Is There A Biosimilar Future For A Smaller Target Like Synagis?
AstraZeneca’s RSV Brand Saw EU And US Patents Run Course Eight Years Ago
Executive Summary
With something of a revolution in the RSV space on the horizon, Generics Bulletin looks at the potential for biosimilar competition in developed markets to AstraZeneca/SOBI’s existing benchmark option, the 25-year-old prophylactic Synagis (palivizumab).